
Hosted by KCAS · EN
"The Weekly Bioanalysis" is a podcast dedicated to discussing Bioanalytical news, tools and services related to the Pharmaceutical, Biopharmaceutical and Biomarker industries. Every month, KCAS will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they've learned about the Bioanalytical world the past couple of weeks.
"The Weekly Bioanalysis" is brought to you by KCAS.KCAS is a progressive growing contract research organization of well over 200 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA and Milan, Italy, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the Pharmaceutical, Biopharmaceutical, Animal Health and Medical Device industries.

Although the world now has a number of vaccines in place and available to serve as a preventative and/or impact-reduction method for COVID, there are a number of reasons that it is also important for the Pharma and Biopharma industries to continue developing other treatment and medicines to for those who become infected - with or without having taken the vaccine. Lucky for all of us, there are a few small molecule agents coming available for COVID patients in 2022, and during episode 51 of "The Weekly Bioanalysis", John and Dom discuss all the small molecule drugs being developed to meet these needs."The Weekly Bioanalysis" is a podcast dedicated to discussing Bioanalytical news, tools and services related to the Pharmaceutical, Biopharmaceutical and Biomarker industries. Twice every month, KCAS will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they've learned about the Bioanalytical world the past couple of weeks. The Weekly Bioanalysis is brought to you by KCAS.KCAS is a progressive growing contract research organization of well over 150 talented and dedicated individuals committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the Pharmaceutical, Biopharmaceutical, Animal Health and Medical Device industries.

It’s an extra special episode of “The Weekly Bioanalysis” as Dom and John celebrate the 50th EPISODE of the official KCAS Podcast by greeting you LIVE in front of the cameras in person for the first time! To watch the video version of the episode, visit this link on KCAS's website: https://kcasbio.com/blog/twb-050As usual, they discuss the news, the industry, and other topics like their recent trip to AAPS in Philadelphia… but for the first time since we began the podcast, they will do it all as they sit right next to one another and talk to YOU “face to face”. Enjoy this special episode – we hope you enjoy watching it as much as we enjoyed producing it together!"The Weekly Bioanalysis" is a podcast dedicated to discussing Bioanalytical news, tools and services related to the Pharmaceutical, Biopharmaceutical and Biomarker industries. Twice every month, KCAS will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they've learned about the Bioanalytical world the past couple of weeks. The Weekly Bioanalysis is brought to you by KCAS.KCAS is a progressive growing contract research organization of well over 150 talented and dedicated individuals committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the Pharmaceutical, Biopharmaceutical, Animal Health and Medical Device industries.

This episode Don and John thought they would talk about something near and dear to our hearts here at KCAS - Antibody-Drug Conjugates. Increasingly we’ve all experienced talk about ADCs everywhere being approved and for various conditions - mostly oncology (drugs used in the treatment of cancer). And of course the point of an ADC is to use the ability of the antibody to deliver an otherwise very toxic drug to the area of interest as safely as possible. KCAS has supported multiple ADC studies both in the Pharmaceutical and Biopharmaceutical devisions, so Dom and John were really excited about this one!"The Weekly Bioanalysis" is a podcast dedicated to discussing Bioanalytical news, tools and services related to the Pharmaceutical, Biopharmaceutical and Biomarker industries. Twice every month, KCAS will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they've learned about the Bioanalytical world the past couple of weeks.The Weekly Bioanalysis is brought to you by KCAS. KCAS is a progressive growing contract research organization of well over 150 talented and dedicated individuals committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the Pharmaceutical, Biopharmaceutical, Animal Health and Medical Device industries.

Sonia Hall, PhD, the CEO of BioKansas, joins Dom and John as our guest for the 49th episode of "The Weekly Bioanalysis". Among a litany of topics, Sonia takes the time to tell the guys about all the amazing things BioKansas does and she gives a breakdown of the many upcoming events planned for the next few months. Both Dom and John are big fans of BioKansas and you can just tell in their voices that they're excited for all the things 2022 sounds like it will bring from Sonia and her team!"The Weekly Bioanalysis" is a podcast dedicated to discussing Bioanalytical news, tools and services related to the Pharmaceutical, Biopharmaceutical and Biomarker industries. Twice every month, KCAS will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they've learned about the Bioanalytical world the past couple of weeks. The Weekly Bioanalysis is brought to you by KCAS.KCAS is a progressive growing contract research organization of well over 150 talented and dedicated individuals committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the Pharmaceutical, Biopharmaceutical, Animal Health and Medical Device industries.

One of the biggest questions on so many people’s minds since the beginning of 2020 has been “how long will it take for an official vaccine to be approved by the FDA?”. It seems the answer has arrived in the form of the approval by the FDA for Pfizer’s COVID-19 Vaccine. Of course, the same vaccine (as well as a number of others) have already been in use for months now, so what exactly is the difference now, and what does it mean moving forward? Dom and John discuss these items – among others – as we all celebrate another impressive achievement within the scientific world on this long road we’ve all been on together."The Weekly Bioanalysis" is a podcast dedicated to discussing Bioanalytical news, tools and services related to the Pharmaceutical, Biopharmaceutical and Biomarker industries. Twice every month, KCAS will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they've learned about the Bioanalytical world the past couple of weeks.The Weekly Bioanalysis is brought to you by KCAS. KCAS is a progressive growing contract research organization of well over 150 talented and dedicated individuals committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the Pharmaceutical, Biopharmaceutical, Animal Health and Medical Device industries.

Dom and John have had a busy summer, and due to recent pressing issues, episode #46 of “The Weekly Bioanlaysis” is an abbreviated version, focusing only on a review of recent news and resources within the industry. Our next episode #47 will focus on the recent announcement that Pfizer’s COVID vaccine has been officially approved by the FDA. Please come back and check that one out – and as always – please continue sending your thoughts, feedback and ideas for podcast episode topics!"The Weekly Bioanalysis" is a podcast dedicated to discussing Bioanalytical news, tools and services related to the Pharmaceutical, Biopharmaceutical and Biomarker industries. Twice every month, KCAS will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they've learned about the Bioanalytical world the past couple of weeks.The Weekly Bioanalysis is brought to you by KCAS. KCAS is a progressive growing contract research organization of well over 150 talented and dedicated individuals committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the Pharmaceutical, Biopharmaceutical, Animal Health and Medical Device industries.

Dom and John often like to feature each of the groups within our industry that contribute to the success of the team, and recently, one of those groups that they were asked about was Program Management. Both of them see first hand the benefit of having a dedicated program management team at a CRO like KCAS, and while we have often showcased others within our organization, it felt like it was time to shine a light on a too often unsung hero of customer relationships. For this episode, Dom and John invite Chris Young, the director of KCAS's Program Management team, to join them as we discuss the role his team plays and why it is so important."The Weekly Bioanalysis" is a podcast dedicated to discussing Bioanalytical news, tools and services related to the Pharmaceutical, Biopharmaceutical and Biomarker industries. Twice every month, KCAS will bring you another 45-60 minutes of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they've learned about the Bioanalytical world the past couple of weeks.The Weekly Bioanalysis is brought to you by KCAS. KCAS is a progressive growing contract research organization of well over 150 talented and dedicated individuals committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the Pharmaceutical, Biopharmaceutical, Animal Health and Medical Device industries.

A number of COVID variants have popped up throughout the life of our podcast, but we’re all hearing more and more stories coming out about the struggles and new challenges surrounding the Delta variant. Despite the encouraging rise in the number of vaccinated, a number of countries have seen an alarming spread of the Delta variant, leading to concern around the globe. For episode #44 of “The Weekly Bioanalysis”, Dom and John thought they would discuss basic virus mutation, how we measure transmissibility, the way variants progress (and why), and what we all should continue to expect in a world of new COVID variants."The Weekly Bioanalysis" is a podcast dedicated to discussing Bioanalytical news, tools and services related to the Pharmaceutical, Biopharmaceutical and Biomarker industries. Twice every month, KCAS will bring you another 45-60 minutes of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and brief themselves on what they've learned about the Bioanalytical world the past week.The Weekly Bioanalysis is brought to you by KCAS. KCAS is a progressive growing contract research organization of well over 150 talented and dedicated individuals committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the Pharmaceutical, Biopharmaceutical, Animal Health and Medical Device industries.

Apologies from the Producer for the shorter length of this episode. We had planned to air a recorded podcast episode on a topic we already knew had the potential to become somewhat controversial, but as the news on this topic progressed between the time of recording and publishing of this episode, we all felt the nature of the material was best left shelved – at least for the moment. Perhaps someday we will publish the “full” episode #43 of “The Weekly Bioanalysis”, but for now it will remain a “News and Updates” episode from Dom and John."The Weekly Bioanalysis" is a podcast dedicated to discussing Bioanalytical news, tools and services related to the Pharmaceutical, Biopharmaceutical and Biomarker industries. Every week, KCAS will bring you another 45-60 minutes of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and brief themselves on what they've learned about the Bioanalytical world the past week.The Weekly Bioanalysis is brought to you by KCAS. KCAS is a progressive growing contract research organization of well over 100 talented and dedicated individuals committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the Pharmaceutical, Biopharmaceutical, Animal Health and Medical Device industries.

As more and more of America (and the world) become fully vaccinated, there are still many questions from everyone, regardless of whether they have been vaccinated. For the 42nd episode of “The Weekly Bioanalysis” podcast, Dom and John discuss many of these questions by giving a sort of “State of Play” with COVID vaccines, as well as looking ahead at what’s next for Vaccines – and even what the “next generation” of vaccines might look like with so many around the globe forming a different perception about them."The Weekly Bioanalysis" is a podcast dedicated to discussing Bioanalytical news, tools and services related to the Pharmaceutical, Biopharmaceutical and Biomarker industries. Every week, KCAS will bring you another 45-60 minutes of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and brief themselves on what they've learned about the Bioanalytical world the past week.The Weekly Bioanalysis is brought to you by KCAS. KCAS is a progressive growing contract research organization of well over 100 talented and dedicated individuals committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the Pharmaceutical, Biopharmaceutical, Animal Health and Medical Device industries.